# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

A 510(k) Number K192943   
B Applicant Microgenics Corporation   
C Proprietary and Established Names CEDIA Heroin Metabolite (6-AM) assay   
D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>DJG</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 862.3650 -Opiate Test System</td><td rowspan=1 colspan=1>TX - ClinicalToxicology</td></tr></table>

# II Submission/Device Overview:

A Purpose for Submission:

Clearance of the CEDIA Heroin Metabolite (6-AM) assay on the Horiba Pentra C400 clinical chemistry analyzer.

# B Measurand:

Heroin Metabolite, 6-Acetylmorphine (6-AM).

# C Type of Test:

# III Intended Use/Indications for Use:

# A Intended Use(s):

See Indications for Use below.

# B Indication(s) for Use:

The CEDIA Heroin Metabolite (6-AM) Assay is a homogeneous enzyme immunoassay for the in vitro qualitative and/or semi-quantitative determination of the presence of heroin metabolite (6- AM) in human urine at a cut-off concentration of $1 0 ~ \mathrm { { n g / m L } }$ . The assay is intended to be used in laboratories and provides a rapid analytical screening procedure to detect 6-Acetylmorphine in human urine. The assay is designed for use with a number of clinical chemistry analyzers. This product is intended to be used by trained professionals only.

The semi-quantitative mode is for the purpose of enabling laboratories to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as Liquid Chromatography/tandem mass spectrometry (LC-MS/MS) or permitting laboratories to establish quality control procedures.

The assay provides only a preliminary analytical test result. A more specific alternative chemical method must be used to obtain a confirmed analytical result. Gas chromatography/ mass spectrometry (GC/MS) or Liquid chromatography with tandem mass spectrometry (LCMS/MS) is the preferred confirmatory method.

Clinical and professional judgment should be applied to any drug of abuse test result, particularly when preliminary results are used. For In Vitro Diagnostic Use Only.

# C Special Conditions for Use Statement(s):

Rx - For Prescription Use Only

For in vitro diagnostic use only.

# D Special Instrument Requirements:

Performance characteristics studies were conducted on the Horiba Pentra C400 clinical chemistry analyzer.

# IV Device/System Characteristics:

# A Device Description:

CEDIA Heroin Metabolite (6-AM) Assay is supplied as a two liquid buffers (1 and 2) and two lyophilized reagents (1a and 1b) kit that is available in a kit configuration of $3 \mathrm { x l } 7 \mathrm { m L }$ .

Kit Constituents: 1 EA Reconstitution Buffer: Contains $0 . 3 2 \mathrm { m g / L }$ mouse monoclonal antibodies to 6- Acetylmorphine, buffer salts, stabilizer, detergent and preservative

1a EA Reagent: Contains $0 . 1 7 1 \ \mathrm { g / L }$ Enzyme Acceptor, buffer salts, detergent and preservative.

2 ED Reconstitution Buffer: Contains buffer salts, stabilizer, and preservative

2a ED Reagent: Contains $1 6 . 2 \mu \mathrm { g / L }$ Enzyme Donor conjugated to 6-Acetylmorphine, $1 . 6 7 \ \mathrm { g / L }$ chlorophenol red- $\beta$ -D galactopyranoside, stabilizer, detergent, preservative.

# B Principle of Operation:

CEDIA technology uses recombinant DNA technology to produce a homogeneous enzyme immunoassay system. The assay is based on the bacterial enzyme $\beta$ -galactosidase, which has been genetically engineered into two inactive fragments. These fragments spontaneously reassociate to form fully active enzymes that, in the assay format, cleave a substrate. This generates a color change that can be measured spectrophotometrically.

In the CEDIA Heroin Metabolite (6-AM) Assay, the analyte in the sample competes with 6-AM conjugated to Enzyme Donor (ED) for antibody binding sites. If 6-AM is present in the sample, it binds to antibody, leaving the ED-6-AM conjugate free to re-associate with Enzyme Acceptor (EA) to form active $\beta \mathrm { . }$ -galactosidase. If no 6-AM is present in the sample, antibody binds to the ED-6-AM conjugate, inhibiting the re-association of inactive -galactosidase fragments, and thus reducing the amount of active enzyme formed. The amount of active enzyme formed, and resultant absorbance change are proportional to the amount of 6-AM present in the sample.

V Substantial Equivalence Information:

A Predicate Device Name(s): CEDIA Heroin Metabolite (6-AM) Assay

B Predicate 510(k) Number(s):

K173183

C Comparison with Predicate(s):

<table><tr><td colspan="1" rowspan="1">Device &amp; PredicateDevice(s):</td><td colspan="1" rowspan="1">K192943</td><td colspan="1" rowspan="1">K173183</td></tr><tr><td colspan="1" rowspan="1">Device Trade Name</td><td colspan="1" rowspan="1">CEDIA HeroinMetabolite (6-AM) Assay</td><td colspan="1" rowspan="1">CEDIA HeroinMetabolite (6-AM) Assay</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristic Similarities</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Intended Use/IndicationsFor Use</td><td colspan="1" rowspan="1">Homogeneous enzymeimmunoassay for the invitro qualitative and/orsemi-quantitativedetermination of thepresence of heroinmetabolite (6-AM) inhuman urine at a cut-offconcentration of 10ng/mL.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Operating Principle(Technology)</td><td colspan="1" rowspan="1">CEDIA</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Measured Analyte</td><td colspan="1" rowspan="1">Heroin and 6-Acetylmorphine</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Test Matrix</td><td colspan="1" rowspan="1">Urine</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Cutoff Levels</td><td colspan="1" rowspan="1">10 ng/mL</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Methodology</td><td colspan="1" rowspan="1">Homogeneous EnzymeImmunoassay</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reagents Form</td><td colspan="1" rowspan="1">EA and ED:Lyophilized(ReconstitutionRequired)EARB and EDRB liquidready-to-use.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Antibody</td><td colspan="1" rowspan="1">Mouse Monoclonalantibody</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Storage</td><td colspan="1" rowspan="1">28°C until expirationdate.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Principal Operator</td><td colspan="1" rowspan="1">Trained professionals</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristic Differences</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Instrument used forperformance characteristicsstudies</td><td colspan="1" rowspan="1">Horiba Pentra C400</td><td colspan="1" rowspan="1">Beckman AU680</td></tr></table>

# VI Standards/Guidance Documents Referenced:

CLSI EP05-A3: Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline - Third Edition; 2014.   
• CLSI EP06-A: Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; 2003.   
• CLSI EP07-A2: Interference Testing in Clinical Chemistry; Approved Guideline - Second Edition; 2005.   
• CLSI EP25-A: Evaluation of Stability in In Vitro Diagnostic Reagents; Approved Guideline; 2009.

# VII Performance Characteristics (if/when applicable):

# A Analytical Performance:

All analytical performance studies were conducted on the Horiba Pentra C400 clinical chemistry analyzer.

Precision studies were performed in accordance with CLSI Guideline EP05-A3 at one site with one analyzer and two lots of reagents. The study was performed for 20 days with two runs per day, at least two hours apart and two replicates per run in both Qualitative and Semiquantitative modes, giving a total of 80 determinants $( \mathrm { n } = 8 0 )$ ). Drug-free negative urine was spiked with 6-Acetylmorphine analyte to final concentrations of $- 1 0 0 \%$ , $- 7 5 \%$ , $- 5 0 \%$ , $- 2 5 \%$ , below cutoff, at cutoff and $+ 2 5 \%$ , $+ 5 0 \%$ , $+ 7 5 \%$ and $+ 1 0 0 \%$ , above cutoff. The concentration of the spiked samples was confirmed by LC-MS/MS or GC/MS. The results from a representative lot are summarized in the tables below.

Qualitative Results:   

<table><tr><td rowspan=2 colspan=1>6-AcetylmorphineConcentration(ng/mL)</td><td rowspan=2 colspan=1>% of Cutoff(10 ng/mL)</td><td rowspan=1 colspan=2>Total Precision (n=80)</td></tr><tr><td rowspan=1 colspan=1>Number ofDeterminations</td><td rowspan=1 colspan=1>ImmunoassayResults(Negative/Positive)</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>-100</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80/0</td></tr><tr><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>-75</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80/0</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>-50</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80/0</td></tr><tr><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>-25</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80/0</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>25/55</td></tr><tr><td rowspan=1 colspan=1>12.5</td><td rowspan=1 colspan=1>+25</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0/80</td></tr><tr><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>+50</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0/80</td></tr><tr><td rowspan=1 colspan=1>17.5</td><td rowspan=1 colspan=1>+75</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0/80</td></tr><tr><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>+100</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0/80</td></tr></table>

Semi-Quantitative Results:   

<table><tr><td rowspan=2 colspan=1>6-AcetylmorphineConcentration(ng/mL)</td><td rowspan=2 colspan=1>% of Cutoff(10 ng/mL)</td><td rowspan=1 colspan=2>Total Precision (n=80)</td></tr><tr><td rowspan=1 colspan=1>Number ofDeterminations</td><td rowspan=1 colspan=1>ImmunoassayResults(Negative/Positive)</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>-100</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80/0</td></tr><tr><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>-75</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80/0</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>-50</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80/0</td></tr><tr><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>-25</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80/0</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>46/34</td></tr><tr><td rowspan=1 colspan=1>12.5</td><td rowspan=1 colspan=1>+25</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0/80</td></tr><tr><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>+50</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0/80</td></tr><tr><td rowspan=1 colspan=1>17.5</td><td rowspan=1 colspan=1>+75</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0/80</td></tr><tr><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>+100</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0/80</td></tr></table>

# 2. Analytical Recovery and Dilution Linearity:

To demonstrate linearity of the assay throughout the calibration range of 0 to $2 0 ~ \mathrm { n g / m L }$ , a drug free–urine pool spiked with 6-AM at $2 0 ~ \mathrm { n g / m L }$ was serially diluted with drug free urine to generate ten intermediate levels. Each sample was run in replicates of five in semi

quantitative mode and the average was used to determine percent recovery compared to the expected target value. The observed result (y) and the target expected result $\mathbf { \tau } ( \mathbf { x } )$ were compared using the least squares regression method. The regression equation and correlation obtained are:

$$
\mathbf { y } = 0 . 9 6 9 2 \mathbf { x } + 0 . 4 9 2 3 ; \mathbf { r } ^ { 2 } = 0 . 9 9 8 6
$$

The recovery of the samples from the linear range of the assay $\mathrm { 0 \ n g / m L }$ to $2 0 \mathrm { n g / m L }$ prepared by dilution ranged from $9 7 . 3 \%$ to $1 1 5 . 6 \%$ .

<table><tr><td rowspan=1 colspan=1>Level</td><td rowspan=1 colspan=1>TargetConcentration(ng/mL)</td><td rowspan=1 colspan=1>ObservedConcentration(ng/mL)</td><td rowspan=1 colspan=1>AverageRecovery (%)</td><td rowspan=1 colspan=1>RecoveryRange(ng/mL)</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.39</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2.31</td><td rowspan=1 colspan=1>115.6</td><td rowspan=1 colspan=1>92.0  134.0</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>4.62</td><td rowspan=1 colspan=1>115.6</td><td rowspan=1 colspan=1>100.8 - 130.5</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>6.25</td><td rowspan=1 colspan=1>104.2</td><td rowspan=1 colspan=1>97.7 - 113.5</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>8.04</td><td rowspan=1 colspan=1>100.5</td><td rowspan=1 colspan=1>94.6 - 106.5</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10.19</td><td rowspan=1 colspan=1>101.9</td><td rowspan=1 colspan=1>97.0 - 108.4</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>12.33</td><td rowspan=1 colspan=1>102.7</td><td rowspan=1 colspan=1>99.6 - 105.1</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>14.36</td><td rowspan=1 colspan=1>102.6</td><td rowspan=1 colspan=1>98.3 - 106.1</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>15.81</td><td rowspan=1 colspan=1>98.8</td><td rowspan=1 colspan=1>95.4 - 100.1</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>18.27</td><td rowspan=1 colspan=1>101.5</td><td rowspan=1 colspan=1>98.1  103.3</td></tr><tr><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>19.46</td><td rowspan=1 colspan=1>97.3</td><td rowspan=1 colspan=1>95.5 - 99.0</td></tr></table>

# 3. Analytical Specificity/Interference:

Cross-reactivity:

Cross-reactivity of the structurally related and unrelated compounds with the performance of the candidate device was evaluated by adding known amounts of each compound to drugfree negative urine. The samples were tested in duplicate with the candidate device in both the qualitative and semi-quantitative modes. Percent cross-reactivity, in semi-quantitative mode, is calculated as follows: $\%$ Cross-reactivity $=$ (Cutoff concentration / Lowest concentration of cross reactant that gives a positive result) $\textbf { x } 1 0 0$

The results are summarized below:

Cross Reactivity of Structurally Related and Unrelated Opiate Compounds   

<table><tr><td rowspan=1 colspan=1>Heroin Metabolite (6-AM) andits metabolites</td><td rowspan=1 colspan=1>TestedConcentration(ng/mL)</td><td rowspan=1 colspan=1>Positive/Negative</td><td rowspan=1 colspan=1>Cross-reactivity(%)</td></tr><tr><td rowspan=1 colspan=1>6-Acetylmorphine</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Heroin</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>8.3</td></tr></table>

<table><tr><td colspan="1" rowspan="1">Structurally related compoundsand other opiates</td><td colspan="1" rowspan="1">TestedConcentration(ng/mL)</td><td colspan="1" rowspan="1">Positive/Negative</td><td colspan="1" rowspan="1">Cross-reactivity(%)</td></tr><tr><td colspan="1" rowspan="1">6-Acetylcodeine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">&lt;0.01</td></tr><tr><td colspan="1" rowspan="1">Buprenorphine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">&lt;0.01</td></tr><tr><td colspan="1" rowspan="1">Buprenorphine-3β-D-glucuronide</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">&lt;0.01</td></tr><tr><td colspan="1" rowspan="1">Codeine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">&lt;0.01</td></tr><tr><td colspan="1" rowspan="1">Dextromethorphan</td><td colspan="1" rowspan="1">90,000</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">0.01</td></tr><tr><td colspan="1" rowspan="1">Dihydrocodeine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">&lt;0.01</td></tr><tr><td colspan="1" rowspan="1">EDDP</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">&lt;0.01</td></tr><tr><td colspan="1" rowspan="1">EMDP</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">&lt;0.01</td></tr><tr><td colspan="1" rowspan="1">Ethylmorphine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">&lt;0.01</td></tr><tr><td colspan="1" rowspan="1">Fentanyl</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">&lt;0.01</td></tr><tr><td colspan="1" rowspan="1">Hydrocodone</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">&lt;0.01</td></tr><tr><td colspan="1" rowspan="1">Hydromorphone</td><td colspan="1" rowspan="1">20,000</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">0.05</td></tr><tr><td colspan="1" rowspan="1">Hydromorphone-3β-D-glucuronide</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">&lt;0.01</td></tr><tr><td colspan="1" rowspan="1">LAAM</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">&lt;0.01</td></tr><tr><td colspan="1" rowspan="1">Levorphanol</td><td colspan="1" rowspan="1">15,000</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">0.07</td></tr><tr><td colspan="1" rowspan="1">Methadone</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">&lt;0.01</td></tr><tr><td colspan="1" rowspan="1">Meperidine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">&lt;0.01</td></tr><tr><td colspan="1" rowspan="1">Mitragynine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">&lt;0.01</td></tr><tr><td colspan="1" rowspan="1">7-Hydroxymitragynine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">&lt;0.01</td></tr><tr><td colspan="1" rowspan="1">Morphine</td><td colspan="1" rowspan="1">13,500</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">0.07</td></tr><tr><td colspan="1" rowspan="1">Morphine-3β-D-Glucuronide</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">&lt;0.01</td></tr><tr><td colspan="1" rowspan="1">Morphine-6β-D-Glucuronide</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">&lt;0.01</td></tr><tr><td colspan="1" rowspan="1">Nalorphine</td><td colspan="1" rowspan="1">10,500</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">0.1</td></tr><tr><td colspan="1" rowspan="1">Naloxone</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">&lt;0.01</td></tr><tr><td colspan="1" rowspan="1">Naltrexone</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">&lt;0.01</td></tr><tr><td colspan="1" rowspan="1">Norbuprenorphine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">&lt;0.01</td></tr><tr><td colspan="1" rowspan="1">Norbuprenorphine glucuronide</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">&lt;0.01</td></tr><tr><td colspan="1" rowspan="1">Norcodeine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">&lt;0.01</td></tr><tr><td colspan="1" rowspan="1">Norhydrocodone</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">&lt;0.01</td></tr><tr><td colspan="1" rowspan="1">Normorphine</td><td colspan="1" rowspan="1">50,000</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">0.02</td></tr><tr><td colspan="1" rowspan="1">Norpropoxyphene</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">&lt;0.01</td></tr><tr><td colspan="1" rowspan="1">Noroxycodone</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">&lt;0.01</td></tr><tr><td colspan="1" rowspan="1">Noroxymorphone</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">&lt;0.01</td></tr><tr><td colspan="1" rowspan="1">Oxycodone</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">&lt;0.01</td></tr><tr><td colspan="1" rowspan="1">Oxymorphone</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">&lt;0.01</td></tr><tr><td colspan="1" rowspan="1">Oxymorphone-3β-D-glucuronide</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">&lt;0.01</td></tr><tr><td colspan="1" rowspan="1">Tapentadol HCI</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">&lt;0.01</td></tr><tr><td colspan="1" rowspan="1">Tramadol</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">&lt;0.01</td></tr></table>

Interference with Commonly Used Drugs:

Interference from commonly co-administered drugs with 6-AM was evaluated by spiking these compounds into urine samples containing 6-AM at $+ / - 2 5 \%$ of the cut-off levels (7.5 $\mathrm { n g / m L }$ and $1 2 . 5 \mathrm { n g / m L }$ ). The samples were tested in duplicate with the candidate device in both the qualitative and semi-quantitative modes. The following list of potentially interfering compounds showed no interference at the indicated concentration when tested with the candidate device.

<table><tr><td colspan="1" rowspan="2">Potential Interferents</td><td colspan="1" rowspan="2">SpikedConcentration(ng/mL)</td><td colspan="2" rowspan="1">Spiked 6-Acetylmorphine Level</td></tr><tr><td colspan="1" rowspan="1">7.5 ng/mL</td><td colspan="1" rowspan="1">12.5 ng/mL</td></tr><tr><td colspan="1" rowspan="1">10,11 Dihydrocarbamazepine</td><td colspan="1" rowspan="1">85,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">11-nor-Δ9-THC-COOH</td><td colspan="1" rowspan="1">10,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Acetaminophen</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Acetylsalicylic Acid</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Amitriptyline</td><td colspan="1" rowspan="1">125,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Amoxicillin</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Amphetamine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Amisulpride</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Benzotropine Mesylate</td><td colspan="1" rowspan="1">125,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Benzoylecgonine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Brompheniramine</td><td colspan="1" rowspan="1">75,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Caffeine</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Captopril</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Chlordiazepoxide</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Chlorpromazine</td><td colspan="1" rowspan="1">10,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Clomipramine</td><td colspan="1" rowspan="1">250,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Chloroquine</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Cimetidine</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Desipramine</td><td colspan="1" rowspan="1">125,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Diazepam</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Digoxin</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Diphenhydramine</td><td colspan="1" rowspan="1">50,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Doxepine HCl</td><td colspan="1" rowspan="1">50,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Enalapril</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Fluoxetine</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Fluophenazine</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Haloperidol</td><td colspan="1" rowspan="1">50,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Hydroxychlroquine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Hydroxyzine</td><td colspan="1" rowspan="1">250,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Ibuprofen</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Imipramine</td><td colspan="1" rowspan="1">50,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Levothyroxine</td><td colspan="1" rowspan="1">50,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Methamphentamine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Maprotiline</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Nalbuphine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Naproxen</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Nortriptyline</td><td colspan="1" rowspan="1">250,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Nifedipine</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Nordiazepam</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Oxazepam</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Perphenazine</td><td colspan="1" rowspan="1">150,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Phencyclidine</td><td colspan="1" rowspan="1">7,500</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Phenobarbital</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Procyclidine</td><td colspan="1" rowspan="1">400,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Propoxyphene</td><td colspan="1" rowspan="1">25,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Protriptyline</td><td colspan="1" rowspan="1">50,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Ranitidine</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Salicyluric Acid</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Secobarbital</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Sulpiride</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Thioridazine</td><td colspan="1" rowspan="1">250,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Triprolidine</td><td colspan="1" rowspan="1">125,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Verapamil</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Positive</td></tr></table>

Interference with Endogenous Substances:

The potential interference of endogenous physiologic substances on recovery of 6-AM using the candidate device was assessed by spiking these potentially interfering substances into drug free urine spiked with 6-AM at $7 . 5 ~ \mathrm { n g / m L }$ and $1 2 . 5 ~ \mathrm { { n g / m L } }$ concentrations. The samples were tested in replicates of five with the candidate device in both the qualitative and semiquantitative modes. In the presence of the compounds listed below, the controls are detected accurately, indicating that these compounds do not interfere with the candidate device.

<table><tr><td rowspan=2 colspan=1>Compound</td><td rowspan=2 colspan=1>TestedConcentration(mg/dL)</td><td rowspan=1 colspan=2>Spiked 6-Acetylmorphine Level</td></tr><tr><td rowspan=1 colspan=1>7.5 ng/mL</td><td rowspan=1 colspan=1>12.5 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Acetone</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Ascorbic acid</td><td rowspan=1 colspan=1>1500</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Creatinine</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Ethanol</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Galactose</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>r-globulin</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Glucose</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Human serum albumin</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Oxalic acid</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Riboflavin</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Sodium Chloride</td><td rowspan=1 colspan=1>6000</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Urea</td><td rowspan=1 colspan=1>2000</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr></table>

Effect of pH:

The pH of drug-free urine samples was adjusted to be pH 3, 4, 5, 6, 7, 8, 9, 10 and 11, and the samples were spiked with 6-AM to $+ / - 2 5 \%$ of the cutoff $( 7 . 5 \mathrm { n g / m L }$ and $1 2 . 5 \mathrm { n g / m L }$ ). The samples were tested in replicates of five with the candidate device in both the qualitative and semi-quantitative modes. The results demonstrated that the $\mathsf { p H }$ does not affect the performance of the candidate.

<table><tr><td rowspan=2 colspan=1>pH</td><td rowspan=1 colspan=2>Spiked 6-Acetylmorphine Concentration</td></tr><tr><td rowspan=1 colspan=1>7.5 ng/mL</td><td rowspan=1 colspan=1>12.5 ng/mL</td></tr><tr><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>7.0</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>9.0</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>11.0</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr></table>

Effect of Specific Gravity:

The specific gravity of drug-free urine samples was adjusted ranging in value within 1.002 to 1.029. These samples were split and spiked to a final concentration of either $7 . 5 ~ \mathrm { n g / m L }$ or $1 2 . 5 ~ \mathrm { { n g / m L } }$ of 6-AM $( + / - 2 5 \%$ of the cutoff). The samples were tested in replicates of five with the candidate device in both the qualitative and semi-quantitative modes. The results demonstrated that specific gravity of the urine in the range 1.002 to 1.029 does not affect the performance of the candidate.

<table><tr><td rowspan=2 colspan=1>SpecificGravity</td><td rowspan=1 colspan=2>Spiked 6-Acetylmorphine Concentration</td></tr><tr><td rowspan=1 colspan=1>7.5 ng/mL</td><td rowspan=1 colspan=1>12.5 ng/mL</td></tr><tr><td rowspan=1 colspan=1>1.002</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>1.004</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>1.005</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>1.007</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>1.010</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>1.012</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>1.014</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>1.019</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>1.023</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>1.025</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>1.029</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr></table>

4. Assay Reportable Range: Not applicable.

The open reagent vial, reagent on-board, reconstituted reagent and real time reagent stability data was reviewed under the premarket submission k173183.

6. Detection Limit: Not applicable.

7. Assay Cut-Off: See section VII.A.1.

# B Comparison Studies:

1. Method Comparison with Predicate Device:

A method comparison study was conducted using one lot of the reagents. One hundred and three unaltered clinical samples were analyzed using the candidate device in one replicate in both the qualitative and semi-quantitative modes and the results were compared to LCMS/MS. The results obtained in the qualitative and semi-quantitative modes are summarized below:

Qualitative Results   

<table><tr><td rowspan=1 colspan=1>CandidateDeviceResults</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>&lt; 50% ofCutoffconcentrationbyLC-MS/MS(&lt; 5ng/mL)</td><td rowspan=1 colspan=1>Near CutoffNegative (Between50% below thecutoff and thecutoffconcentration asdetermined byLC-MS/MS)(5.0 - 9.9 ng/mL)</td><td rowspan=1 colspan=1>Near CutoffPositive (Betweenthe cutoff and50% above thecutoffconcentration asdetermined byLC-MS/MS)(10 - 15.0 ng/mL)</td><td rowspan=1 colspan=1>High Positives(Greater than50% abovecutoffconcentration(&gt; 15.0 ng/mL)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>45</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

Semi-Quantitative Results   

<table><tr><td rowspan=1 colspan=1>CandidateDeviceResults</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>&lt; 50% ofCutoffconcentrationbyLC-MS/MS(&lt; 5ng/mL)</td><td rowspan=1 colspan=1>Near CutoffNegative (Between50% below thecutoff and thecutoffconcentration asdetermined byLC-MS/MS)(5.0 - 9.9 ng/mL)</td><td rowspan=1 colspan=1>Near CutoffPositive (Betweenthe cutoff and50% above thecutoffconcentration asdetermined byLC-MS/MS)(10 - 15.0 ng/mL)</td><td rowspan=1 colspan=1>High Positives(Greater than50% abovecutoffconcentration(&gt; 15.0 ng/mL)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>45</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

2. Matrix Comparison: Not applicable.

# C Clinical Studies:

1. Clinical Sensitivity: Not applicable.

2. Clinical Specificity: Not applicable.

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable): None.

D Clinical Cut-Off: Not applicable.   
E Expected Values/Reference Range: Not applicable.

# VIII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.